Hovione has launched a new service to provide proof of concept formulation for new dry powder formulations within a few weeks. The company says that its Rapid Proof of Concept Study will further simplify DPI development and reduce the time required for development projects.
Hovione VP of Pharma & Innovation Peter Villax commented, “This new Rapid Proof of Concept service offers clients a low risk look at the feasibility of developing a DPI product and gives clients greater confidence about going into later stage development. Clients of the new service don’t just get a report, they get their first DPI formulation.”
“In a short period of time and for relatively little investment,” Hovione suggests, “a drug developer can acquire a DPI formulation, potentially adding significant value to an early stage out-licensing opportunity or helping a company move into a stronger position in funding negotiations with venture capitalists.”
Read the Hovione press release.
